Peter Humphrey, MD, PhD, Discusses Histology and Clinical Trial Enrollment in RCC

Video

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Peter Humphrey, MD, PhD, spoke about how enrollment for specific trials in renal cell carcinoma may incorporate a patient’s tumor histology.

CancerNetwork® spoke with Peter Humphrey, MD, PhD, professor of pathology and director of Genitourinary Pathology at Yale School of Medicine in New Haven, Connecticut, about how clinicians can best identify patients with renal cell carcinoma who may be eligible to enroll on a clinical trial. Humphrey spoke about this topic at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, hosted by Physicians’ Education Resource®, LLC (PER®).

Transcript:

I can’t really speak to clinical trials, there’s so many ongoing. I think the oncologists [may] be the best doctors to speak to that. I would say that as far as trials, it is important to know that histology can influence enrollment. For example, there were trials presented [at the conference] where the enrollment in 1 trial was based upon a diagnosis of papillary renal cell carcinoma. Other times, it’s [based on] enrollment of clear cell versus non–clear cell renal cell [carcinoma]. Again, knowing the classification of renal cell carcinoma can help [physicians] better understand what the specific aim of the trial might be in targeting a specific type of renal cell carcinoma.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Related Content